News

Novo Nordisk (NVO): The trial data for Novo Nordisk’s experimental obesity shot CagriSema showed a lack of clear advantage ...
A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...